These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29439772)

  • 1. Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.
    Chambers MS; Rugo HS; Litton JK; Meiller TF
    J Am Dent Assoc; 2018 Apr; 149(4):291-298. PubMed ID: 29439772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
    Jones VE; McIntyre KJ; Paul D; Wilks ST; Ondreyco SM; Sedlacek S; Melnyk A; Oommen SP; Wang Y; Peck SR; O'Shaughnessy JA
    Oncologist; 2019 Sep; 24(9):1153-1158. PubMed ID: 30833486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors.
    Pilotte AP; Hohos MB; Polson KM; Huftalen TM; Treister N
    Clin J Oncol Nurs; 2011 Oct; 15(5):E83-9. PubMed ID: 21951751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.
    Peterson DE; O'Shaughnessy JA; Rugo HS; Elad S; Schubert MM; Viet CT; Campbell-Baird C; Hronek J; Seery V; Divers J; Glaspy J; Schmidt BL; Meiller TF
    Cancer Med; 2016 Aug; 5(8):1897-907. PubMed ID: 27334013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian target of rapamycin inhibitor-associated stomatitis.
    Boers-Doets CB; Raber-Durlacher JE; Treister NS; Epstein JB; Arends AB; Wiersma DR; Lalla RV; Logan RM; van Erp NP; Gelderblom H
    Future Oncol; 2013 Dec; 9(12):1883-92. PubMed ID: 24295418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.
    Sonis S; Treister N; Chawla S; Demetri G; Haluska F
    Cancer; 2010 Jan; 116(1):210-5. PubMed ID: 19862817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of Stomatitis: Using Dexamethasone-Based Mouthwash to Inhibit Everolimus-Related Stomatitis.
    Saigal B; Guerra L
    Clin J Oncol Nurs; 2018 Apr; 22(2):211-217. PubMed ID: 29547614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
    Lo Muzio L; Arena C; Troiano G; Villa A
    Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R; Lacouture M; Wu S
    Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus.
    Kalogirou EM; Tosios KI; Piperi EP; Sklavounou A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Jan; 119(1):e13-9. PubMed ID: 25442249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors.
    Sonis ST; Villa A
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical presentation and management of mTOR inhibitor-associated stomatitis.
    de Oliveira MA; Martins E Martins F; Wang Q; Sonis S; Demetri G; George S; Butrynski J; Treister NS
    Oral Oncol; 2011 Oct; 47(10):998-1003. PubMed ID: 21890398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer patients have increased risk of developing mTOR inhibitor-associated stomatitis.
    de Lima M; Hajj G; de Lima V; Alves FA
    Oral Dis; 2018 Mar; 24(1-2):207-209. PubMed ID: 29480592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.
    Alvarez RH; Bechara RI; Naughton MJ; Adachi JA; Reuben JM
    Oncologist; 2018 Jun; 23(6):660-669. PubMed ID: 29487226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus: side effect profile and management of toxicities in breast cancer.
    Paplomata E; Zelnak A; O'Regan R
    Breast Cancer Res Treat; 2013 Aug; 140(3):453-62. PubMed ID: 23907751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin: biological function and target for novel anticancer agents.
    Borders EB; Bivona C; Medina PJ
    Am J Health Syst Pharm; 2010 Dec; 67(24):2095-106. PubMed ID: 21116000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.
    Ng VC; Johnson JJ; Cuellar S
    J Oncol Pharm Pract; 2015 Dec; 21(6):433-42. PubMed ID: 24964967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa.
    Sonis S; Andreotta PW; Lyng G
    Oral Dis; 2017 Apr; 23(3):347-352. PubMed ID: 27896917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.
    Divers J; O'Shaughnessy J
    Clin J Oncol Nurs; 2015 Aug; 19(4):468-74. PubMed ID: 26207713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.
    Rugo HS; Seneviratne L; Beck JT; Glaspy JA; Peguero JA; Pluard TJ; Dhillon N; Hwang LC; Nangia C; Mayer IA; Meiller TF; Chambers MS; Sweetman RW; Sabo JR; Litton JK
    Lancet Oncol; 2017 May; 18(5):654-662. PubMed ID: 28314691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.